Using Genetics to Prevent & Treat Pediatric Cancer

After decades of clinical breakthroughs, Dana-Farber has helped increase survival rates and new treatment options for children with cancer. Yet, childhood cancer is still the leading cause of disease-related death in children in the United States. To help overcome this challenge, Dana-Farber’s Pediatric Cancer Genetic Risk Program brings together a team of physicians, genetic counselors, and researchers to help manage all aspects of genetic cancer risk. This discussion is about how Dana-Farber is leading the way in transforming the prevention and treatment of cancer in children. Panelists were joined by a patient family member with firsthand experience with this program.

Give Now

Thank you for your interest in learning more about The Dana-Farber Campaign. You have been added to our email list and will receive updates on ways to join us in defying cancer. You can unsubscribe at any time.

There has been an issue submitting your request. Please try again.

Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and a federally designated Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries throughout the world. About Our Patient Stories: Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.